The role of hepatocyte-specific staining in liver pathology

References

• Bellin MF, Vasile M, Morel-Precetti S. Currently used non-specific extracellular MR contrast media. Eur. Radiol.13, 2688–2698 (2003).
   PubMed Web of Science ®Google Scholar
• Semelka RC, Martin DR, Balci C et al. Focal liver lesions: comparison of dual phase CT and multisequence multiplanar MR imaging including dynamic gadolinium enhancement. J. Magn. Reson. Imaging13, 397–401 (2001).
   PubMed Web of Science ®Google Scholar
• Balci NC, Semelka RC. Contrast agents for MR imaging of the liver. Radiol. Clin. North Am.43, 887–898 (2005).
   PubMed Web of Science ®Google Scholar
• Reimer P, Jahnke N, Fiebich M et al. Hepatic lesion detection and characterization: value of nonenhanced MR imaging, superparamagnetic iron oxide-enhanced MR imaging and spiral CT: ROC analysis. Radiology217, 152–158 (2000).
   PubMed Web of Science ®Google Scholar
• Bluemke DA, Paulson EK, Choti MA et al. Detection of hepatic lesions in candidates for surgery: comparison of ferumoxide-enhanced MR imaging and dual phase helical CT. AJR Am. J. Roentgenol.175, 1653–1658 (2000).
   PubMed Web of Science ®Google Scholar
• Braga HJ, Choti MA, Lee VS et al. Liver lesion: manganese-enhanced MR and dual phase helical CT for preoperative detection and characterization. Comparison with receiver operating characteristics analysis. Radiology223, 525–531 (2002).
   PubMed Web of Science ®Google Scholar
• Bartolozzi C, Donati F, Cioni D et al. Detection of colorectal liver metastases: a prospective multicenter trial comparing unenhanced MRI, Mn-DPDP enhanced MRI and spiral CT. Eur. Radiol.14, 14–20 (2004).
   PubMed Web of Science ®Google Scholar
• Van Montfoort JE, Stieger B, Meijer DK, Weinmann HJ, Meier PJ, Fattinger KE. Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide OATP1 . J. Pharmacol. Exp. Ther.290(1), 153–157 (1999).
   PubMed Web of Science ®Google Scholar
• Lorusso V, Pascolo L, Fernetti C, Visigalli M, Anelli P, Tiribelli C. In vitro and in vivo hepatic transport of the magnetic resonance imaging contrast agent B22956/1: role of MRP proteins. Biochem. Biophys. Res. Commun.293(1), 100–105 (2002).
   PubMed Web of Science ®Google Scholar
• Spinazzi A, Lorusso V, Pirovano G, Kirchin M. Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. Acad. Radiol.6, 282–291 (1999).
   PubMed Web of Science ®Google Scholar
• Petersein J, Spinazzi A, Giovagnoni A et al. Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging – a multicenter Phase III clinical study. Radiology215, 727–736 (2000).
   PubMed Web of Science ®Google Scholar
• Kuwatsuru R, Kadoya M, Ohtomo K et al. Clinical late Phase II trials of MultiHance (Gd-BOPTA) for the magnetic resonance imaging of liver tumors in Japan. J. Comput. Assist. Tomogr.23(Suppl. 1), S65–S74 (1999).
   PubMed Web of Science ®Google Scholar
• Narita M, Hatano E, Arizono S et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J. Gastroenterol.44, 793–798 (2009).
   PubMed Web of Science ®Google Scholar
• Hamm B, Staks T, Muhler A et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology195, 785–792 (1995).
   PubMed Web of Science ®Google Scholar
• Reimer P, Rummeny EJ, Shamsi K et al. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology199, 177–183 (1996).
   PubMed Web of Science ®Google Scholar
• Yamashita Y, Hatanaka Y, Yamamoto H et al. Differential diagnosis of focal liver lesions: role of spin-echo and contrast-enhanced dynamic MR imaging. Radiology193, 59–65 (1994).
   PubMed Web of Science ®Google Scholar
• Semelka RC, Brown ED, Ascher SM et al. Hepatic hemangiomas: a multi-institutional study of appearance on T2 weighted and serial gadolinium-enhanced gradient-echo MR images. Radiology192, 401–406 (1994).
   PubMed Web of Science ®Google Scholar
• Hussain SM, Terkivatan T, Zondervan PE et al. Focal nodular hyperplasia: findings at state-of-the-art MR imaging, US, CT and pathologic analysis. Radiographics24, 3–17 (2004).
   PubMed Web of Science ®Google Scholar
• Mortelé KJ, Praet M, Van Vherberghe H, Kunnen M, Ros PR. CT and MRI imaging findings in focal nodular hyperplasia of the liver: radiologic-pathologic correlation. AJR Am. J. Roentgenol.175, 687–692 (2000).
   PubMed Web of Science ®Google Scholar
• Zech CJ, Grazioli L, Breuer J, Reiser MF, Schoenberg SO. Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial. Invest. Radiol.43, 504–511 (2008).
   PubMed Web of Science ®Google Scholar
• Ba-Ssalamah A, Schima W, Schmook MT et al. Atypical focal nodular hyperplasia of the liver: imaging features of nonspecific and liver-specific MR contrast agents. AJR Am. J. Roentgenol.179, 1447–1456 (2002).
   PubMed Web of Science ®Google Scholar
• Grazioli L, Morana G, Federle MP et al. Focal nodular hyperplasia: morphological and functional information from MR imaging with gadobenate dimeglumine. Radiology221, 731–739 (2001).
   PubMed Web of Science ®Google Scholar
• Grazioli L, Federle MP, Brancatelli G, Ichikawa T, Olivetti L, Blachar A. Hepatic adenomas imaging and pathologic findings. Radiographics21(4), 877–892 (2001).
   PubMed Web of Science ®Google Scholar
• Ichikawa T, Federle MP, Grazioli L et al. Hepatocellular adenoma: multiphasic CT and pathologic findings in 25 patients. Radiology214, 861–868 (2000).
   PubMed Web of Science ®Google Scholar
• Cantwell CP, Setty BN, Holalkere N, Sahani DY, Fischman AJ, Blake MA. Liver lesion detection and characterization in patients with colorectal cancer: a comparison of low radiation dose non-enhanced PET/CT, contrast enhanced PET/CT and liver MRI. J. Comput. Assist. Tomogr.32, 738–744 (2008).
   PubMed Web of Science ®Google Scholar
• Bipat S, van Leeuwen MS, Comans EF et al. Colorectal liver metastases: CT, MR imaging and PET for diagnosis – meta-analysis. Radiology237, 123–131 (2005).
   PubMed Web of Science ®Google Scholar
• Floriani I, Torri V, Rulli E, et al. Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer – a systematic review and meta-analysis. J. Magn. Reson. Imaging31, 19–31 (2010).
   PubMed Web of Science ®Google Scholar
• Schneider G, Maas R, Schultze Kool L et al. Low dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intraindividual crossover comparison. Invest. Radiol.38, 85–94 (2003).
   PubMed Web of Science ®Google Scholar
• Kulemann V, Schima W, Tamandl D et al. Preoperative detection of colorectal liver metastases in fatty liver: MDCT or MRI? Eur. J. Radiol. DOI: 10.1016/j.ejrad.2010.03.004 (2010) (Epub ahead of print).
   Google Scholar
• Ward J. New MR techniques for the detection of liver metastases. Cancer Imaging6, 33–42 (2006).
   PubMedGoogle Scholar
• Efremidis SC, Hytiroglou P. The multistep process of hepatocarcinogenesis in cirrhosis with imaging correlation. Eur. Radiol.12, 753–764 (2002).
   PubMed Web of Science ®Google Scholar
• Kudo M, Tomita S, Kashida H et al. Tumor hemodynamics in hepatic nodules associated with liver cirrhosis: relationship between cancer progression and tumor hemodynamic change. Nippon Shokakibyo Gakkai Zasshi88, 1554–1565 (1991).
   PubMedGoogle Scholar
• Bruix J, Sherman M, Practice guidelines committee, American association for the study of liver diseases. Management of hepatocellular carcinoma. Hepatology42, 1208–1236 (2005).
   PubMed Web of Science ®Google Scholar
• Kim MJ, Choi JY, Chung YE, Choi SY. Magnetic resonance imaging of hepatocellular carcinoma using contrast media. Oncology75(Suppl. 1), 72–82 (2008).
   PubMedGoogle Scholar
• Kudo M. The 2008 Okuda lecture: management of hepatocellular carcinoma from surveillance to molecular targeted therapy. J. Gastroenterol. Hepatol.25, 439–452 (2010).
   PubMed Web of Science ®Google Scholar
• Ahn SS, Kim MJ, Lim JS, Hong HS, Chung YE, Choi JY. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology255, 459–466 (2010).
   PubMed Web of Science ®Google Scholar
• Choi SH, Lee JM, Yu NC et al. Hepatocellular carcinoma in liver transplantation candidates: detection with gadobenate dimeglumine enhanced MRI. AJR Am. J. Roentgenol.191, 529–536 (2008).
   PubMed Web of Science ®Google Scholar
• Bartolozzi C, Crocetti L. Lencioni R, Cioni D, Della Pina C, Campani D. Biliary and reticuloendothelial impairment in hepatocarcinogenesis: the diagnostic role of tissue-specific MR contrast media. Eur. Radiol.17, 2519–2530 (2007).
   PubMed Web of Science ®Google Scholar
• Saito K, Kotake F, Ito N et al. Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. Magn. Reson. Med. Sci.4, 1–9 (2005).
   PubMedGoogle Scholar
• Hemming AW, Cattral MS, Reed AI, Van Der Werf WJ, Greig PD, Howard RJ. Liver transplantation for hepatocellular carcinoma. Ann. Surg.233, 652–659 (2001).
   PubMed Web of Science ®Google Scholar
• Sun HY, Lee JM, Shim CI et al. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or = 2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Invest. Radiol.45, 96–103 (2010).
   PubMed Web of Science ®Google Scholar
• Markos SK. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br. J. Radiol.80(950), 73–76 (2007).
   PubMed Web of Science ®Google Scholar
• Thomsen HS, Marckmannb P, Logager VB. Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents. Cancer Imaging7, 130–137 (2007).
   PubMedGoogle Scholar
• Schwartz LH, Gaudras EJ, Colangelo SM et al. Prevalence and importance of small hepatic lesions found at CT in patients with cancer. Radiology210, 71–74 (1999).
   PubMed Web of Science ®Google Scholar